Literature DB >> 9828857

Increases in CD4+ T lymphocytes, macrophages, neutrophils and interleukin 8 positive cells in the airways of patients with bronchiectasis.

M Gaga1, A M Bentley, M Humbert, J Barkans, F O'Brien, C G Wathen, A B Kay, S R Durham.   

Abstract

BACKGROUND: Bronchiectasis is a chronic suppurative lung disease characterised by irreversible dilation of the bronchi and persistent purulent sputum. The immunopathology of the disease was studied using a quantitative immunostaining technique with particular reference to T lymphocytes, macrophages, and granulocytes.
METHODS: Bronchial mucosal biopsy specimens were obtained by fibreoptic bronchoscopy from 12 patients with bronchiectasis (six receiving inhaled steroids) and 11 normal healthy controls. Immunostaining (APAAP method) was performed on frozen cryostat sections with a panel of monoclonal antibodies to total leucocytes (CD45), T lymphocyte phenotypic markers (CD3, CD4, CD8), macrophages (CD68), eosinophils (EG2), and neutrophils (elastase).
RESULTS: There was a mononuclear cell infiltrate in both patients with bronchiectasis and normal controls, but an overall increase in total leucocyte cell numbers (CD45+ cells) was identified in those with bronchiectasis (median values 422 cells/mm2 versus 113 cells/mm2 in control tissue, p < 0.001). Intense infiltration of CD3+ T lymphocytes was observed compared with healthy controls (292 cells/mm2 and 40 cells/mm2, respectively, p < 0.001). This comprised predominantly CD4+ T cells (118 cells/mm2) rather than CD8+ T cells (47 cells/mm2). CD3+ cells counts were reduced in those subjects on inhaled steroids compared with those not receiving inhaled steroids (197 cells/mm2 versus 369 cells/mm2, p < 0.05), as were CD4+ cell counts (82 cells/mm2 versus 190 cells/mm2, p < 0.05). Neutrophil and macrophage cell numbers were also increased in patients with bronchiectasis (114 cells/mm2 and 213 cells/mm2, respectively) compared with controls (41 neutrophils/mm2 and 40 macrophages/mm2). EG2+ (activated) eosinophil numbers were much lower than T cells, macrophages, and neutrophils in patients with bronchiectasis but were increased compared with controls (36 cells/mm2 versus 0 cells/mm2, p < 0.001). In view of the markedly increased neutrophil counts in patients with bronchiectasis, biopsy specimens were immunostained for interleukin 8 (IL-8) which was highly significantly increased compared with controls (47 cells/mm2 versus 15 cells/mm2, p < 0.01). IL-8+ cells were less prominent in steroid treated patients than in patients not receiving treatment (30 cells/mm2 versus 60 cells/mm2, p < 0.05). A further characteristic of bronchiectasis was mucous gland hypertrophy. Gland area comprised up to 40% of the tissue in some bronchiectasis sections while no hypertrophy was noted in control biopsy specimens (p < 0.05).
CONCLUSION: Airway inflammation in bronchiectasis is characterised by tissue neutrophilia, a mononuclear cell infiltrate composed mainly of CD4+ T cells and CD68+ macrophages, and increased IL-8 expression. Inhaled corticosteroid treatment in patients with bronchiectasis is associated with a less marked infiltration by T cells and IL-8+ cells within the bronchial mucosa, although this finding requires confirmation in a prospective placebo controlled trial.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9828857      PMCID: PMC1745299          DOI: 10.1136/thx.53.8.685

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  26 in total

1.  Measurement of the bronchial mucous gland layer: a diagnostic yardstick in chronic bronchitis.

Authors:  L REID
Journal:  Thorax       Date:  1960-06       Impact factor: 9.139

2.  Impaired tracheobronchial clearance in bronchiectasis.

Authors:  D C Currie; D Pavia; J E Agnew; M T Lopez-Vidriero; P D Diamond; P J Cole; S W Clarke
Journal:  Thorax       Date:  1987-02       Impact factor: 9.139

3.  Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis.

Authors:  M Saetta; A Di Stefano; P Maestrelli; A Ferraresso; R Drigo; A Potena; A Ciaccia; L M Fabbri
Journal:  Am Rev Respir Dis       Date:  1993-02

4.  Multivariate analysis of factors affecting pulmonary function in bronchiectasis.

Authors:  M Ip; I J Lauder; W Y Wong; W K Lam; S Y So
Journal:  Respiration       Date:  1993       Impact factor: 3.580

5.  Effect of antibiotics on sputum inflammatory contents in acute exacerbations of bronchiectasis.

Authors:  M Ip; D Shum; I Lauder; W K Lam; S Y So
Journal:  Respir Med       Date:  1993-08       Impact factor: 3.415

6.  Alkaline phosphatase and peroxidase for double immunoenzymatic labelling of cellular constituents.

Authors:  D Y Mason; R Sammons
Journal:  J Clin Pathol       Date:  1978-05       Impact factor: 3.411

7.  Activated T lymphocytes of the synovial membrane in rheumatoid arthritis and other arthropathies.

Authors:  L W Poulter; O Duke; G S Panayi; S Hobbs; M J Raftery; G Janossy
Journal:  Scand J Immunol       Date:  1985-12       Impact factor: 3.487

8.  Mucus hypersecretion in bronchiectasis. The role of neutrophil proteases.

Authors:  J V Fahy; A Schuster; I Ueki; H A Boushey; J A Nadel
Journal:  Am Rev Respir Dis       Date:  1992-12

9.  Ciliary disorientation in patients with chronic upper respiratory tract inflammation.

Authors:  C F Rayner; A Rutman; A Dewar; P J Cole; R Wilson
Journal:  Am J Respir Crit Care Med       Date:  1995-03       Impact factor: 21.405

10.  The relationship between infiltrating CD4+ lymphocytes, activated eosinophils, and the magnitude of the allergen-induced late phase cutaneous reaction in man.

Authors:  A J Frew; A B Kay
Journal:  J Immunol       Date:  1988-12-15       Impact factor: 5.422

View more
  29 in total

1.  Persistent sputum cellularity and neutrophils may predict bronchiectasis.

Authors:  Nicole Drost; Liesel D'silva; Ryan Rebello; Ann Efthimiadis; Frederick E Hargreave; Parameswaran Nair
Journal:  Can Respir J       Date:  2011 Jul-Aug       Impact factor: 2.409

Review 2.  Positive expiratory pressure therapy versus other airway clearance techniques for bronchiectasis.

Authors:  Annemarie L Lee; Angela T Burge; Anne E Holland
Journal:  Cochrane Database Syst Rev       Date:  2017-09-27

Review 3.  Diagnosis and management of bronchiectasis.

Authors:  Maeve P Smith
Journal:  CMAJ       Date:  2017-06-19       Impact factor: 8.262

4.  Airway Clearance Techniques in Bronchiectasis: Analysis From the United States Bronchiectasis and Non-TB Mycobacteria Research Registry.

Authors:  Ashwin Basavaraj; Radmila Choate; Doreen Addrizzo-Harris; Timothy R Aksamit; Alan Barker; Charles L Daley; M Leigh Anne Daniels; Edward Eden; Angela DiMango; Kevin Fennelly; David E Griffith; Margaret M Johnson; Michael R Knowles; Mark L Metersky; Peadar G Noone; Anne E O'Donnell; Kenneth N Olivier; Matthias A Salathe; Andreas Schmid; Byron Thomashow; Gregory Tino; Kevin L Winthrop
Journal:  Chest       Date:  2020-07-03       Impact factor: 9.410

Review 5.  Autoinflammatory disease in the lung.

Authors:  Thomas Scambler; Jonathan Holbrook; Sinisa Savic; Michael F McDermott; Daniel Peckham
Journal:  Immunology       Date:  2018-04-19       Impact factor: 7.397

Review 6.  Is there a role for inhaled corticosteroids and macrolide therapy in bronchiectasis?

Authors:  Paul King
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 7.  Airway clearance techniques for bronchiectasis.

Authors:  Annemarie L Lee; Angela T Burge; Anne E Holland
Journal:  Cochrane Database Syst Rev       Date:  2015-11-23

8.  Could vitamin d have a potential anti-inflammatory and anti-infective role in bronchiectasis?

Authors:  Jim Bartley; Jeff Garrett; Cameron C Grant; Carlos A Camargo
Journal:  Curr Infect Dis Rep       Date:  2013-04       Impact factor: 3.725

Review 9.  Role of macrolide therapy in chronic obstructive pulmonary disease.

Authors:  Fernando J Martinez; Jeffrey L Curtis; Richard Albert
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

Review 10.  The pathophysiology of bronchiectasis.

Authors:  Paul T King
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.